June is #CancerSurvivorsMonth. We celebrate the strength, resilience & determination of cancer survivors everywhere. Their experiences inspire hope, drive progress & remind us why advancing cancer research matters. To all survivors: we honor your journey.💜#ClinicalTrials
Premenopausal pts w/ER+/HER2- #breastcancer who remain at high risk for recurrence may benefit from intensified systemic therapy strategies. Yesterday at #ASCO26, Dr. Mamounas discussed NRG-BR009 OFSET, a study evaluating the addition of chemotherapy to OFS + endocrine therapy.
Tomorrow at #ASCO26, Dr. Rastogi discusses legacy NSABP B-28 study during a poster session. B-28 was a randomized trial comparing the worth of paclitaxel following doxorubicin/ cyclophosphamide in patients with #breastcancer and who had positive axillary nodes. @NSABPFoundation
Surrounded by some of the brightest minds and strongest leaders in oncology at #ASCO26, our NSABP team is proud to be a part of the meaningful progress in cancer research.
The NSABP FC-13 poster will be presented today by @AnwaarSaeed3 at #ASCO26. The FC-13 trial is studying cemiplimab monotherapy or cemiplimab-based combos in pts with #colorectalcancer & MRD after definitive therapy. J Clin Oncol 44, 2026 (suppl 16; abstr TPS3685)
From groundbreaking science to practice-changing clinical research, NRG Oncology is proud to have a strong presence at #ASCO26. Take a look at the impactful NRG Oncology research being presented at #ASCO26. #CancerResearch#ClinicalTrials#Oncology
Have communications experience and want to learn more about RTOG? We are now accepting applications for our July 2026- July 2027 RTOG Foundation Communications Interns. More details: https://t.co/v7G0YX1jnr Applications due JUNE 10TH
Don't miss these upcoming podcast episodes on results presented during #ASCO26. Topics: Updated OS analysis of NRG-GY018 w/ @rne_md & the a combined analysis of prostate cancer studies w/ @krishnan_patel & @APDicker: https://t.co/PPnktscHlO
The NSABP Foundation Operations Office and Pathology are closed today, May 25, 2026 in observance of the Memorial Day holiday. Regular business hours resume tomorrow.
Join us in Denver for #NRG2026 Summer Meeting! Featuring scientific sessions, early-career education, networking, expanded symposium & more! Register by June 23 to avoid late fee! https://t.co/uVKfeBQgvU
Attending #ASCO26? The NSABP FC-13 poster will be presented by @AnwaarSaeed3 on May 30th. The FC-13 trial is studying cemiplimab monotherapy or cemiplimab-based combos in pts with #colorectalcancer & MRD after definitive therapy. J Clin Oncol 44, 2026 (suppl 16; abstr TPS3685)
Behind every advance in cancer care is a #clinicaltrial made possible by patients, caregivers & clinical research teams working together. On #ClinicalTrialsDay, we celebrate collaboration, dedication & innovation driving progress for patients everywhere. #CTD2026#ResearchRising
The OFSET study is evaluating whether adding chemotherapy to ovarian function suppression + endocrine therapy can improve outcomes compared to standard hormonal treatment alone for premenopausal patients with high-risk ER-positive/HER2-negative #breastcancer. Learn more⤵️
#Clinicaltrialresearch is vital. "Every new medicine and treatment started with volunteers participating in clinical trials." You can support the work of the NSABP Foundation today: https://t.co/8UUHriPx0O #NSABPFoundation#CancerResearch
National Nurses Week 2026 is May 6-12. The week-long celebration always starts on May 6 #NationalNursesDay and ends on May 12, honoring the birthday of Florence Nightingale. The 2026 theme from ANA is "The Power of Nurses" #ThankANurse
Since inception in 1957, the NSABP Foundation has designed and led numerous clinical trials pioneering new standards for treating breast and colorectal cancer. https://t.co/G7DCb7cjSS
May is #BrainCancerAwarenessMonth. The NRG-CC017 trial builds on early data suggesting TMPRT may extend survival while preserving memory & cognitive function. This phase III study will test its benefit in a large, randomized setting. Learn more➡️ https://t.co/sZEWFnfXga